Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Summary: Background: The latest French good practice recommendations (GPR s) for the screening, prevention, and treatment of alcohol misuse were recently published in partnership with the European Federation of Addiction Societies (EUFAS). This article aims to synthesize the GPR s focused on the pharmacotherapy of alcohol dependence. Methods: A four‐member European steering committee defined the questions that were addressed to an 18‐member multiprofessional working group (WG). The WG developed the GPR s based on a systematic, hierarchical, and structured literature search and submitted the document to two review processes involving 37 French members from multiple disciplines and 5 non‐French EUFAS members. The final GPR s were graded A, B, or C, or expert consensus (EC) using a reference recommendation grading system. Results: The treatment of alcohol dependence consists of either alcohol detoxification or abstinence maintenance programs or drinking reduction programs. The therapeutic objective is the result of a decision made jointly by the physician and the patient. For alcohol detoxification, benzodiazepines (BZD s) are recommended in first‐line (grade A). BZD dosing should be guided by regular clinical monitoring (grade B). Residential detoxification is more appropriate for patients with a history of seizures, delirium tremens, unstable psychiatric comorbidity, or another associated substance use disorder (grade B). BZD s are only justified beyond a 1‐week period in the case of persistent withdrawal symptoms, withdrawal events or associated BZD dependence (grade B). BZD s should not be continued for more than 4 weeks (grade C). The dosing and duration of thiamine (vitamin B1) during detoxification should be adapted to nutritional status (EC). For relapse prevention, acamprosate and naltrexone are recommended as first‐line medications (grade A). Disulfiram can be proposed as second‐line option in patients with sufficient information and supervision (EC). For reducing alcohol consumption, nalmefene is indicated in first line (grade A). The second‐line prescription of baclofen, up to 300 mg/day, to prevent relapse or reduce drinking should be carried out according to the “temporary recommendation for use” measure issued by the French Health Agency (EC). During pregnancy, abstinence is recommended (EC). If alcohol detoxification is conducted during pregnancy, BZD use is recommended (grade B). No medication other than those for alcohol detoxification should be initiated in pregnant or breastfeeding women (EC). In a stabilized pregnant patient taking medication to support abstinence, the continuation of the drug should be considered on a case‐by‐case basis, weighing the benefit/risk ratio. Only disulfiram should be always stopped, given the unknown risks of the antabuse effect on the fetus (EC). First‐line treatments to help maintain abstinence or reduce drinking are off‐label for people under 18 years of age and should thus be considered on a case‐by‐case basis after the repeated failure of psychosocial measures alone (EC). Short half‐life BZD s should be preferred for the detoxification of elderly patients (grade B). The initial doses of BZD s should be reduced by 30 to 50% in elderly patients (EC). In patients with chronic alcohol‐related physical disorders, abstinence is recommended (EC). Any antidepressant or anxiolytic medication should be introduced after a psychiatric reassessment after 2–4 weeks of alcohol abstinence or low‐risk use (grade B). A smoking cessation program should be offered to any smokers involved in an alcohol treatment program (grade B).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Practice Guideline: Otitis Media with Effusion (Update)
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., et al. (2016) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815623467 · Cited by 2,006
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 2×
“13 The indication for and tailoring of BZD treatment should be guided by regular and rigorous clinical surveillance, which may be supported by withdrawal symptom evaluation scales (CIWA-Ar scale [31] or Cushman score [32]) B”
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 1×
“Both acamprosate and naltrexone have been demonstrated to be efficacious for relapse prevention (37–39), and they display a globally good level of tolerability (37).”
Harm reduction approaches to alcohol use
Marlatt, G. A., & Witkiewitz, K. (2002) · Addictive Behaviors · doi:10.1016/s0306-4603(02)00294-0 · Cited by 491 · cited 1×
“Such programs aim to target the patients for whom the classical abstinence-based treatment strategies are unappealing or unattainable [3] and thus to reduce the important treatment gap observed among patients with AUDs [4].”
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Jørgensen, C. H., Pedersen, B., & Tønnesen, H. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01523.x · Cited by 366
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347 · cited 2×
“It is worth mentioning that the drug’s specific mode of action implies that double-blind designs are not adequate (41).”
Self-citationGRANT, J. D., SCHERRER, J. F., LYNSKEY, M. T., LYONS, M. J., EISEN, S. A., TSUANG, M. T., TRUE, W. R., & BUCHOLZ, K. K. (2006) · Psychological Medicine · doi:10.1017/s0033291705006045 · Cited by 321 · cited 1×
“Because the overall prognosis is less favorable in such situations [63], abstinence is often the preferred goal (grade C).”
Identification of behaviour change techniques to reduce excessive alcohol consumption
Michie, S., Whittington, C., Hamoudi, Z., Zarnani, F., Tober, G., & West, R. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03845.x · Cited by 288
Wikner, B. N., Stiller, C., Bergman, U., Asker, C., & Källén, B. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1457 · Cited by 253
Cited by
Carvalho, A. F., Heilig, M., Perez, A., Probst, C., & Rehm, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31775-1 · Cited by 671
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172
Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93
Self-citationMelby, K., Gråwe, R. W., Aamo, T. O., Salvesen, Ø., & Spigset, O. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.01.003 · Cited by 33
Benzodiazepine dependence in subjects with alcohol use disorders: what prevalence?
Morel, A., Grall-Bronnec, M., Bulteau, S., Chauvin-Grelier, P., Gailledrat, L., Pinot, M. L., Jolliet, P., & Victorri-Vigneau, C. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221922 · Cited by 25
A Bayesian meta-analysis of topiramate’s effectiveness for individuals with alcohol use disorder
Fluyau, D., Kailasam, V. K., & Pierre, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221149643 · Cited by 20
Lux-Battistelli, C., & Battistelli, D. (2017) · Medicine · doi:10.1097/md.0000000000008861 · Cited by 13
Metadata
- Authors
- Rolland, B., Paille, F., Gillet, C., Rigaud, A., Moirand, R., Dano, C., Dematteis, M., Mann, K., & Aubin, H.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2015-12-17
- Volume
- 22
- Issue
- 1
- Pages
- 25-37
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2198390448
- Cited by
- 120
- References
- 13
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.